We are looking for adults between the ages of 18 and 75, currently taking 1 to 2 antidepressants, to take part in a clinical study.
The PACE-1 Study is helping researchers learn more about an investigational treatment for Treatment-Resistant Depression (TRD). TRD is a form of depression that does not improve, or only improves a little bit, after trying at least 2 different antidepressant medications, as prescribed by your doctor. Qualified participants will receive payment for their study-related time and travel.
To learn more about participating in this study, visit ClinicalTrials.gov or contact the study site at contact@piedmontneurosciencecenter.com or (510) 630-1201. Qualified participants will receive payment for their study-related time and travel.
This study is looking at the effects of lithium in adults living with chronic traumatic brain injury (TBI). It’s aimed at learning whether lithium may help improve long-term symptoms related to past brain injury.
To learn more or see if you may qualify, contact the study site at contact@piedmontneurosciencecenter.com or (510) 630-1201.
This Phase III study looked at COMP360, a psilocybin-based treatment given with psychological support, in adults with treatment-resistant depression (TRD). Participants received one or two administrations, and the study assessed how well the treatment worked, how safe it was, and how well it was tolerated over time.
Learn more at ClinicalTrials.gov.
This study evaluated whether a simple blood test measuring plasma P-tau217 could help doctors identify early signs of Alzheimer’s-related brain changes in patients with memory or thinking concerns. The goal was to see if this test could support earlier, more accurate diagnosis and guide treatment decisions
sooner.
Learn more at ClinicalTrials.gov.
Please contact us directly at 510-630-1201 with any questions or scheduling inquiries you may have.